Literature DB >> 19830706

PDEF is a negative regulator of colon cancer cell growth and migration.

Omar Moussa1, David P Turner, Ron J Feldman, Victor I Sementchenko, Brent D McCarragher, Mohamed M Desouki, Mostafa Fraig, Dennis K Watson.   

Abstract

ETS is a family of transcriptional regulators with functions in most biological processes. Dysregulated ETS factor function leads to altered expression of multiple genes that play critical roles in many of the processes required for cancer progression. While the Ets family gene, prostate-derived ETS factor (PDEF), is expressed in epithelial tissues including prostate, breast, and colon, PDEF protein expression has been found to be reduced or lost during prostate and breast cancer progression. The goal of this study was to examine the expression and biologic impact of altered PDEF expression in colon cancer. PDEF mRNA and protein are not detectable in several colon-cancer-derived cell lines. Re-expression of PDEF in colon cancer cells inhibits growth and migration. Growth affects are due to altered cellular proliferation, indicated by increased altered cell population in G(1) and S phases of the cell cycle, as well as increased apoptosis. Relevant to its modulation of growth and migration phenotypes, PDEF expression resulted in altered expression of genes with established roles in cell cycle, motility, and invasion. Furthermore, chromatin immunoprecipitation studies show that p21 and urokinase plasminogen activator (uPA) are direct PDEF transcriptional targets. While non-tumor colon epithelium expresses PDEF mRNA and protein, the majority of tumors showed decreased mRNA and/or protein expression. In human tumor tissue samples, PDEF expression was inversely correlated with the expression levels of uPA. Collectively, the data support the model that PDEF is a negative regulator of tumor progression by modulating the expression of growth and migration promoting genes. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19830706      PMCID: PMC3348703          DOI: 10.1002/jcb.22371

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  36 in total

Review 1.  The morphogenetic code and colon cancer development.

Authors:  Gijs R van den Brink; G Johan Offerhaus
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

2.  Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line.

Authors:  Kunrong Cheng; Guofeng Xie; Jean-Pierre Raufman
Journal:  Biochem Pharmacol       Date:  2006-12-10       Impact factor: 5.858

3.  Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.

Authors:  Michio Nakamura; Shin'ichi Miyamoto; Hiroyuki Maeda; Genichiro Ishii; Takahiro Hasebe; Tsutomu Chiba; Masahiro Asaka; Atsushi Ochiai
Journal:  Biochem Biophys Res Commun       Date:  2005-08-05       Impact factor: 3.575

4.  Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo.

Authors:  Ali Ghadersohi; Dalin Pan; Zahra Fayazi; David G Hicks; Janet S Winston; Fengzhi Li
Journal:  Breast Cancer Res Treat       Date:  2006-08-08       Impact factor: 4.872

Review 5.  ETS transcription factors and their emerging roles in human cancer.

Authors:  Arun Seth; Dennis K Watson
Journal:  Eur J Cancer       Date:  2005-10-06       Impact factor: 9.162

6.  Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer.

Authors:  David P Turner; Omar Moussa; Moira Sauane; Paul B Fisher; Dennis K Watson
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

7.  Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells.

Authors:  Xuesong Gu; Luiz F Zerbini; Hasan H Otu; Manoj Bhasin; Quanli Yang; Marie G Joseph; Franck Grall; Tomi Onatunde; Ricardo G Correa; Towia A Libermann
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

8.  A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in ApcMin/+ mice.

Authors:  V A Ploplis; H Tipton; H Menchen; F J Castellino
Journal:  J Pathol       Date:  2007-11       Impact factor: 7.996

Review 9.  ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.

Authors:  David P Turner; Dennis K Watson
Journal:  Expert Rev Anticancer Ther       Date:  2008-01       Impact factor: 4.512

Review 10.  Defining ETS transcription regulatory networks and their contribution to breast cancer progression.

Authors:  David P Turner; Victoria J Findlay; Omar Moussa; Dennis K Watson
Journal:  J Cell Biochem       Date:  2007-10-15       Impact factor: 4.429

View more
  20 in total

1.  Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.

Authors:  Ali Ghadersohi; Satish Sharma; Shaozeng Zhang; Rami G Azrak; Gregory E Wilding; Masoud H Manjili; Fengzhi Li
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

2.  Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression.

Authors:  David P Turner; Victoria J Findlay; Omar Moussa; Victor I Semenchenko; Patricia M Watson; Amanda C LaRue; Mohamed M Desouki; Mostafa Fraig; Dennis K Watson
Journal:  Prostate       Date:  2011-03-28       Impact factor: 4.104

3.  1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Authors:  Michele N Washington; Nancy L Weigel
Journal:  Endocrinology       Date:  2010-02-10       Impact factor: 4.736

4.  Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.

Authors:  Luciane Rostirola Cavazzola; Gustavo Franco Carvalhal; Candida Deves; Daiana Renck; Ricardo Almeida; DIóGENES Santiago Santos
Journal:  Oncol Lett       Date:  2015-04-01       Impact factor: 2.967

5.  The transcription factor SPDEF suppresses prostate tumor metastasis.

Authors:  Joshua J Steffan; Sweaty Koul; Randall B Meacham; Hari K Koul
Journal:  J Biol Chem       Date:  2012-07-02       Impact factor: 5.157

6.  Prostate-Derived ETS Factor Regulates Epithelial-to-Mesenchymal Transition through Both SLUG-Dependent and Independent Mechanisms.

Authors:  Victoria J Findlay; David P Turner; John S Yordy; Brent McCarragher; Marey R Shriver; Gabor Szalai; Patricia M Watson; Amanda C Larue; Omar Moussa; Dennis K Watson
Journal:  Genes Cancer       Date:  2011-02

7.  SPDEF functions as a colorectal tumor suppressor by inhibiting β-catenin activity.

Authors:  Taeko K Noah; Yuan-Hung Lo; Allison Price; Gang Chen; Eileen King; Mary-Kay Washington; Bruce J Aronow; Noah F Shroyer
Journal:  Gastroenterology       Date:  2013-02-01       Impact factor: 22.682

Review 8.  Signatures of prostate-derived Ets factor (PDEF) in cancer.

Authors:  Nitin Mahajan
Journal:  Tumour Biol       Date:  2016-09-10

9.  PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.

Authors:  Gilles Buchwalter; Michele M Hickey; Anne Cromer; Laura M Selfors; Ruwanthi N Gunawardane; Jason Frishman; Rinath Jeselsohn; Elgene Lim; David Chi; Xiaoyong Fu; Rachel Schiff; Myles Brown; Joan S Brugge
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

10.  Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through decommissioning of a transcriptional enhancer.

Authors:  Sabine Jägle; Kerstin Rönsch; Sylvia Timme; Hana Andrlová; Miriam Bertrand; Marcel Jäger; Amelie Proske; Monika Schrempp; Afsheen Yousaf; Tom Michoel; Robert Zeiser; Martin Werner; Silke Lassmann; Andreas Hecht
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.